Introduction
Cancer is uncontrolled growth of abnormal cells that grow outside their usual boundaries and then assault the adjoining parts of the body and spread to other organs. Cancer is the second leading cause of deaths worldwide and accounted for 8.8 million deaths in 2015.
1 In 2018, 1,735,350 new cancer cases and 609,640 cancer deaths are projected to occur in the United States. 2 There are many types of cancer treatment, and the treatment strategy depends upon cancer type and stage. The most important cancer treatments are chemotherapy, surgery, radiation therapy, immunotherapy, targeted therapy, and hormonal therapy. Stem cell transplant and precision medicine may also help during cancer treatment. 3 Chemotherapy is a major part of cancer therapeutics; however, it has its own limitations of limited efficacy, selectivity, high cost, genotoxicity, and drug resistance. 4 Extensive research and development, especially in the design and discovery anticancer agents, is the need of the present day.
Compounds containing heterocyclic rings are of great importance both in medicine and industry. 5 Oxadiazole is one among the heterocyclic rings and has fascinating diverse biological potentials. Oxadiazoles have a large impact on multiple drug discovery programs across a variety of therapeutic areas, including tuberculosis, 6 cancer, 7 HIV, 8 diabetes, 9 obesity, 10 inflammation, 11 and infection. 12 The carbonyl compounds of amides, ester, carbamates, and hydroxamic acids have been successfully replaced with oxadiazole rings for improved efficacy. 13−15 Similarly, triazole analogues are well reported anticancer agents. 16, 17 The literature on oxadizoles and our previous published work 18 is a source of inspiration to continue research on further exploration of oxadiazole, and in the present investigation we report herein the synthesis and cytotoxicity evaluation of some new oxadiazole analogues. A few triazole analogues were also synthesized and are reported herein.
Results and discussion

Chemistry
As shown in the Scheme, ethyl(2,4-dichlorophenoxy)acetate (3) was synthesized by stirring a mixture of 2,4-dichlorphenol (1) and ethylchloroacetate (2) suspended in acetone and potassium carbonate for 24 h.
18,19
Ethyl(2,4-dichlorophenoxy)acetate (3) was further refluxed with hydrazine hydrate in ethanol for 6 h to synthesize 2-(2,4-dichlorophenoxy)acetohydrazide (4) . 18, 19 In the final step, an equimolar quantity of 2-(2,4-dichlorophenoxy)acetohydrazide (4) and aromatic aldehyde was refluxed in an ethanol/water system (1:2, v/v) solvent by adding 20 mol% NaHSO 3 for 10 h to obtain 2-[(2,4-dichlorophenoxy)methyl]-5-aryl-1,3,4-oxadiazole (5a-h). 12 The progress of the reaction was monitored throughout by thin-layer chromatography (TLC) using n-hexane:ethylacetate (1:1) as mobile phase. Base-catalyzed synthesis of 3-[(2,4-dichlorophenoxy)methyl]-5-aryl-4 H -1,2,4-triazole (5i,j) was achieved by refluxing 2-(2,4-dichlorophenoxy)acetohydrazide (4) and nitrile in n -butanol for 2-3 h in the presence of K 2 CO 3 . 20 The progress of the reactions was monitored throughout by TLC (Silica gel 60 F 254 ) using mobile phase, chloroform-methanol (9:1), and benzene-acetone (9:1). The spots were visualized under either iodine vapor or UV light. All the compounds were obtained in satisfactory yield ranging between 52% and 81%. All the chemicals were procured from CDH (New Delhi, India), Merck (Kenilworth, NJ, USA), and SD Fine (Mumbai, India). The title compounds (5a-j) were further characterized by infrared (IR), nuclear magnetic resonance ( 1 H NMR and 13 C NMR), and mass spectral data. IR, NMR, and mass spectra data were obtained on a Shimadzu 8201 PC (Kyoto, Japan), Bruker AC 400 MHz spectrometer (in DMSO-d 6 ) (Billerica, MA, USA), and Bruker Esquire LCMS using ESI, respectively. The purity of compounds was checked by elemental analyses (PerkinElmer 2400 elemental analyzer, Waltham, MA, USA). In the 1 H NMR, the prototype compound 5e showed a singlet at δ 5.27 ppm corresponding to the protons of CH 2 , a doublet at δ 6.85 ppm corresponding to one aromatic proton, a double doublet at δ 7.11 ppm corresponding to another aromatic proton of 2,4-dichlorophenyl, a multiplet at δ 7.23-7.70 ppm corresponding to the four aromatic protons, a singlet at δ 8.31 ppm corresponding to the one aromatic proton (2,4-dichlorophenyl), and a singlet at δ 10.03 ppm corresponding to the phenolic proton (ArOH). 
Cytotoxicity
All the title compounds (5a-j) were evaluated for their cytotoxicity at 10 µ M drug concentrations as per the National Cancer Institute (NCI) protocol on nine different panels of 59 human cancer cell lines.
21−24
The results of cytotoxicity study are given in Table 1 . All the tested compounds showed moderate or weaker cytotoxicity except for 5e, which showed promising cytotoxicity among the series. The compounds 5a, 5b, 5f, and 5g
showed higher sensitivity towards the UACC 257 (melanoma) [percent growth inhibitions (%GIs) = 43. were considered to be active towards that particular cell line. 25 Compound 5e showed promising cytotoxicity Figure 2 shows the %GIs of 5e and 5-FU on 50 human cancer cell lines in common at 10 µ M drug concentrations. The average %GIs against the nine panels was also calculated for comparative study and 5e showed higher sensitivity towards leukemia, non-small cell lung cancer, CNS cancer, and ovarian cancer ( Table 2 ). The cytotoxicity data of imatinib and 5-FU were obtained from the NCI data warehouse index. The structure activity relationship was established with cytotoxicity studies, and the 2-hydroxy substitution showed the maximum cytotoxicity. The 2-chloro substitution showed higher cytotoxicity than the 4-hydroxy-3-methoxy and nitro substitutions. The order of cytotoxicity in the present investigation was 2-OH > 2-Cl > 4-OH-3-OCH 3 > 4-NO 2 , while the overall activity was 3,4-( 
Conclusion
All the compounds were synthesized in satisfactory yield and evaluated for cytotoxicity on nine different panels of nearly 60 human cancer cell lines. Compound 5e showed promising cytotoxicity among the series of compounds. The growth control (percent growth inhibition) of the compound, 5e, at one dose assay (10 µM) The cytotoxicity of 5e was higher than that of imatinib and comparable to that of 5-FU. The cytotoxicity studies reported herein may provide an insight into the design of other anticancer agents with improved antiproliferative activity.
Experimental
Method for the synthesis of ethyl(2,4-dichlorophenoxy)acetate (3)
Equimolar amounts of 2,4-dichlorophenol (0.05 mol; 5.91 mL) and ethyl chloroacetate (0.05 mol; 5.35 mL) in 50-60 mL acetone, and 5 g anhydrous potassium carbonate were refluxed for 24 h with continuous stirring to obtain ethyl(2,4-dichlorophenoxy)acetate (3). 
Method for the synthesis of 2-(substitutedphenoxy)acetohydrazide (4)
A solution of substituted ethyl(2,4-dichlorophenoxy)acetate (0.03 mol; 7.01 mL) (3) and hydrazine hydrate (0.045 mol; 2.18 mL) was refluxed in ethanol for 5-6 h to obtain 2-(2,4-dichlorophenoxy)acetohydrazide (4).
The solid thus obtained was recrystallized with an absolute ethanol. 
2-[(2,4-Dichlorophenoxy)methyl]-5-phenyl-1,3,4-oxadiazole (5a)
Creamy solid; mp 112-114 
2-[(2,4-Dichlorophenoxy)methyl]-5-(4-fluorophenyl)-1,3,4-oxadiazole (5b)
Creamy solid; mp 118-120 
2-[(2,4-Dichlorophenoxy)methyl]-5-(4-chlorophenyl)-1,3,4-oxadiazole (5c)
White solid; mp 122-124 
Cytotoxicity
The new synthesized compounds were evaluated for their cytotoxicity at 10 µ M drug concentrations as per the NCI protocol on nine different panels of 59 human cancer cell lines. 21−24 The human tumor cell lines were grown in RPMI 1640 medium. The cell lines were inoculated into 96-well microtiter having cell densities 5000-40,000 cells/well and further incubated for 24 h at 37 • C (5% CO 2 , 95% air, and 100% relative humidity)
prior the addition of test compounds. The microtiter plates were incubated for 48 h after addition of test compounds (solution in DMSO) and finally the assay was terminated by addition of trichloroacetic acid (10%).
Sulforhodamine B (SRB) was added and excess SRB was removed washing 5 times with 1% acetic acid, and 
